Docopa

Docopa 400 mg Tablet should be taken orally, with food or milk, to minimize gastrointestinal discomfort. Do not crush or chew the tablet; swallow it whole.

Docopaxib selectively inhibits cyclooxygenase-2 (COX-2) enzyme, which is primarily responsible for the synthesis of prostaglandins involved in pain, inflammation, and fever. By inhibiting COX-2, it reduces these inflammatory responses without significantly affecting COX-1, which protects the stomach lining.

• Hypersensitivity to docopaxib, sulfonamides, or any components of the formulation
• History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
• Active peptic ulceration or gastrointestinal bleeding
• Severe hepatic impairment
• Severe renal impairment (creatinine clearance < 30 mL/min)
• Late stages of pregnancy (third trimester)
• Established ischemic heart disease, peripheral arterial disease, and/or cerebrovascular disease

Store in a cool, dry place below 30°C. Protect from light and moisture. Keep out of reach of children.

Symptoms may include lethargy, drowsiness, nausea, vomiting, and epigastric pain. Gastrointestinal bleeding can occur. Rarely, hypertension, acute renal failure, respiratory depression, and coma may occur. Management: Symptomatic and supportive treatment. Gastric lavage and/or activated charcoal may be considered within the first hour of ingestion.

Pregnancy Category C (first and second trimesters), Category D (third trimester). Avoid in late pregnancy due to potential for premature closure of the ductus arteriosus and impaired renal function in the fetus. Not recommended during breastfeeding as it may pass into breast milk.